Tirzepatide
Also known as: Mounjaro, Zepbound
Brand names: Mounjaro, Zepbound
Tirzepatide is a dual-action peptide approved by the FDA as Mounjaro for type 2 diabetes and Zepbound for weight management. It is the first medication to target both GIP and GLP-1 receptors simultaneously. In the SURMOUNT-1 trial, participants achieved an average weight loss of 22.5% over 72 weeks. This dual mechanism appears to provide superior glycemic control and weight loss compared to GLP-1-only agonists.
Dual GIP/GLP-1 receptor agonist that enhances insulin secretion, reduces glucagon, slows gastric emptying, and decreases appetite
| Parameter | Detail |
|---|---|
| Administration | Subcutaneous injection |
| Typical Dose | 15mg weekly (max dose) |
| Frequency | Weekly |
Common Side Effects
Serious Side Effects
- Personal or family history of medullary thyroid carcinoma
- Multiple endocrine neoplasia syndrome type 2
- Pregnancy
Evidence Quality
Clinical Trial Phase
Approved (post-market)
Average Weight Loss in Trials
22.5%
| Peptide | Monthly Cost | FDA Status |
|---|---|---|
| Tirzepatide | $1100 - $1500/mo | FDA Approved |
| Semaglutide | $1000 - $1400/mo | FDA Approved |
| Retatrutide | $1200 - $1500/mo | Phase 3 |
| AOD-9604 | $30 - $60/mo | Phase 2 |
Medical Disclaimer
The information provided on this page is for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy or medication. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary.